ADAM17 and Miyoshi myopathy: Furthermore, studies have demonstrated that ADAM17 was significantly unregulated in melanomas [24,25], and downregulation of ADAM17 induced by rosmarinic acid resulted in inhibitions in cell growth and migration, and increases in cell apoptosis and cisplatin sensitivity in melanoma cells [25], indicating that ADAM17 serves as an oncogene in MM.